摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5-dichloro-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one; hydrochloride | 65225-82-3

中文名称
——
中文别名
——
英文名称
4,5-dichloro-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one; hydrochloride
英文别名
4,5-dichloro-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one hydrochloride;2-Morpholinoethyl-4,5-dichloro-3(2H)-pyridazinone hydrochloride;4,5-dichloro-2-(2-morpholin-4-ylethyl)pyridazin-3-one;hydrochloride
4,5-dichloro-2-(2-morpholin-4-yl-ethyl)-2<i>H</i>-pyridazin-3-one; hydrochloride化学式
CAS
65225-82-3
化学式
C10H13Cl2N3O2*ClH
mdl
——
分子量
314.599
InChiKey
YOOWVHMUWOUEED-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    45.1
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:1c35ca6de235b3b8a5df278533598430
查看

反应信息

  • 作为反应物:
    描述:
    4,5-dichloro-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one; hydrochloride 生成 8-acetylamino-3-(2-morpholin-4-yl-ethyl)-3H,10H-benzo[b]pyridazino[4,5-e][1,4]thiazin-4-one
    参考文献:
    名称:
    Duro; Pappalardo; Vittorio, Farmaco, Edizione Scientifica, 1978, vol. 33, # 9, p. 676 - 683
    摘要:
    DOI:
  • 作为产物:
    描述:
    4,5-二氯-3-羟基哒嗪 以46%的产率得到
    参考文献:
    名称:
    PAPPALARDO G.; VITTORIO F.; DURO F., FARMACO. ED. SCI., 1977, 32, NO 11, 780-788
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • [EN] 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS<br/>[FR] PYRAZOLES 3,4-DISUBSTITUTES SERVANT D'INHIBITEURS DE KINASES CYCLINES DEPENDANTES (CDK), OU DE KINASES AURORA OU DE GLYCOGENE SYNTASES 3 (GSK-3)
    申请人:ASTEX TECHNOLOGY LTD
    公开号:WO2006003440A1
    公开(公告)日:2006-01-12
    The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: Rq is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR5; X' is NR4', O, S or S(O); A is a bond or -(CH2)m-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group -(CH2)p- wherein p is 2 to 4; and R1 to R6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.
    本发明提供式(I)的化合物;或其盐、溶剂化物或N-氧化物;其中:Rq选自基团(a)、(b)和(c);星号表示与吡唑环的连接点;X为N或CR5;X'为NR4'、O、S或S(O);A为键或-(CH2)m-(B)n-;B为C=O、NRg(C=O)或O(C=O),其中Rg为氢或C1-4烃基,可选择性地被羟基或C1-4烷氧基取代;m为0、1或2;n为0或1;R0为氢,或与存在的NRg一起形成基团-(CH2)p-,其中p为2至4;R1至R6b如说明书中所定义。式(I)的化合物作为CDK、aurora和GSK-3激酶的抑制剂,对于治疗或预防由所述激酶介导的疾病,如癌症,具有用途。
  • 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors
    申请人:Gill Liam Adrian
    公开号:US20080004270A1
    公开(公告)日:2008-01-03
    The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: R q is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR 5 ; X″ is NR 4 ; O, S or S(O); A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R 0 is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; and R 1 to R 6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.
    本发明提供了式(I)的化合物;或其盐、溶剂或N-氧化物;其中:Rq选择自组(a)、(b)和(c);星号表示与吡唑环的连接点;X为N或CR5;X″为NR4;O、S或S(O);A为键或—(CH2)m—(B)n—;B为C═O、NRg(C═O)或O(C═O),其中Rg为氢或C1-4烃基,可选地被羟基或C1-4烷氧基取代;m为0、1或2;n为0或1;R0为氢或与NRg一起,形成—(CH2)p—基团,其中p为2至4;R1至R6如描述中所定义。式(I)的化合物具有作为CDK、极光激酶和GSK-3激酶抑制剂的活性,可用于治疗或预防由该激酶介导的癌症等疾病。
  • Santagati; Duro; Caruso, Farmaco, Edizione Scientifica, 1985, vol. 40, # 12, p. 921 - 929
    作者:Santagati、Duro、Caruso、Trombadore、Amico-Roxas
    DOI:——
    日期:——
  • Pappalardo; Vittorio; Duro, Farmaco, Edizione Scientifica, 1977, vol. 32, # 11, p. 780 - 788
    作者:Pappalardo、Vittorio、Duro
    DOI:——
    日期:——
  • SANTAGATI, N. A.;DURO, F.;CARUSO, A.;TROMBADORE, S.;AMICO-ROXAS, M., FARMACO. ED. SCI., 1985, 40, N 12, 921-929
    作者:SANTAGATI, N. A.、DURO, F.、CARUSO, A.、TROMBADORE, S.、AMICO-ROXAS, M.
    DOI:——
    日期:——
查看更多